The food and Drug Administration (FDA) requires aspire vapor Co., joyetech, vapor and voopoo to provide information on social media and "online Red" marketing strategies.
FDA hopes that data collected from these brands will provide FDA with an effective strategy for the FDA's pre market review application (PMTA) to assess the marketing of related products.
"With growing attention to the marketing of new tobacco end products for adolescents, the FDA is trying to further understand the growing online terminal marketing and adolescent engagement," the FDA said.
An analysis by the tobacco product center (CTP) found that most of the top end brands sell products through a variety of social media platforms, but do not use age limiting tools to prevent the sale of products to teenagers.
In addition, CTP said that atomization companies often have brand ambassadors and influential people who have a large number of fans on social media who can get paid for promoting products.
FDA has selected the four companies to respond to the letter dated March 17 within 60 days. If it does not respond within the deadline, FDA may take mandatory measures.
Earlier this year, the FDA sent a warning letter to 10 atomizing companies that are still producing and selling electronic nicotine delivery system (ends) products to warn them that they did not submit PMTA but are still engaged in the sales of related products.
According to the FDA website, for companies that submit applications before the deadline, the FDA usually delays its execution for one year, pending FDA review unless the FDA rejects the application.
In addition, the FDA announced in September that the PMTA procedures that should normally be kept confidential will be made public in the future and that FDA will publish a list of all products submitted by the deadline. Mitch Zeller, director of the FDA tobacco products center, announced the news on its blog, when the FDA had received about 2000 applications for e-cigarettes and other new tobacco products.
From warning letters to data collection from companies, this suggests that FDA is preparing to move enforcement procedures to a substantive stage.